(New York, NY) – March 10th, 2014 – AiCure, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, exhibited its technology at the 2nd Annual World Congress Summit to Improve Adherence and Enhance Patient Engagement. AiCure showcased AiViewTM as one of the very few technologies able to accurately confirm patient medication administration and offer a viable and cost-effective alternative to DOT. Adam Hanina, chief executive officer, was also invited to lead a roundtable discussion on “The Role of Artificial Intelligence in Adherence and Patient Engagement”. Unlike other technologies such as smart pills or hardware designed to measure medication in a patient’s breath, AiViewTM uses facial recognition software that is available as an app, requiring no changes to the drug manufacturing process or additional hardware. AiViewTM is designed for disease categories requiring DOT or high levels of monitoring, where non-adherence is particularly costly. The technology is also being used to monitor study participants in clinical research.
-
Share
-
Recent Press
-
May 29, 2025
AiCure Appoints Sabina Chadha as CEO, Ed Ikeguchi Transitions to Chief Medical Officer, and Josh Wilson Promoted to COO and President
-
Nov 28, 2024
Clinical Research, Inequality and the Future of Women’s Health
-
Oct 21, 2023
From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
-
May 29, 2025